Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Antiparkinson Agents/adverse effects"'
Autor:
Jan Bert Gramsbergen, Egon Stenager, Nils J. Færgeman, Niels H. H. Heegaard, Andreas Dammann Andersen, Michael Binzer, Jesper F. Havelund, Morten Blaabjerg
Publikováno v:
Havelund, J F, Dammann Andersen, A, Binzer, M, Blaabjerg, M, Heegaard, N H H, Stenager, E, Faergeman, N J & Gramsbergen, J B 2017, ' Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia ', Journal of Neurochemistry, vol. 142, no. 5, pp. 756–766 . https://doi.org/10.1111/jnc.14104
L-3,4-Dihydroxyphenylalanine (L-DOPA) is the most effective drug in the symptomatic treatment of Parkinson's disease, but chronic use is associated with L-DOPA-induced dyskinesia in more than half the patients after 10 years of treatment. L-DOPA trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::340d215018d7f3828a55fa6f729b261b
https://pubmed.ncbi.nlm.nih.gov/28628213
https://pubmed.ncbi.nlm.nih.gov/28628213
Autor:
Schuepbach, W.M., Rau, J., Knudsen, K., Volkmann, J., Krack, P., Timmermann, L., Halbig, T.D., Hesekamp, H., Navarro, S.M., Meier, N., Falk, D., Mehdorn, M., Paschen, S., Maarouf, M., Barbe, M.T., Fink, G.R., Kupsch, A., Gruber, D., Schneider, G.H., Seigneuret, E., Kistner, A., Chaynes, P., Ory-Magne, F., Brefel Courbon, C., Vesper, J., Schnitzler, A., Wojtecki, L., Houeto, J.L., Bataille, B., Maltete, D., Damier, P., Raoul, S., Sixel-Doering, F., Hellwig, D., Gharabaghi, A., Kruger, R., Pinsker, M.O., Amtage, F., Regis, J.M., Witjas, T., Thobois, S., Mertens, P., Kloss, M., Hartmann, A., Oertel, W.H., Post, B., Speelman, H., Agid, Y., Schade-Brittinger, C., Deuschl, G.
Publikováno v:
New England journal of medicine, 368(7), 610-622. Massachussetts Medical Society
Schüpbach, Michael W. M.; Rau, J.; Knudsen, K.; Volkmann, J.; Krack, P.; Timmermann, L.; Hälbig, T. D.; Hesekamp, H.; Navarro, S. M.; Meier, Niklaus; Falk, D.; Mehdorn, M.; Paschen, S.; Maarouf, M.; Barbe, M. T.; Fink, G. R.; Kupsch, A.; Gruber, D.; Schneider, G.-H.; Seigneuret, E.; ... (2013). Neurostimulation for Parkinson's disease with early motor complications. New England journal of medicine NEJM, 368(7), pp. 610-622. Massachusetts Medical Society MMS 10.1056/NEJMoa1205158
The New England Journal of Medicine, 368, 610-22
New England Journal of Medicine, Vol. 368, No 7 (2013) pp. 610-622
The New England Journal of Medicine, 368, 7, pp. 610-22
Schüpbach, Michael W. M.; Rau, J.; Knudsen, K.; Volkmann, J.; Krack, P.; Timmermann, L.; Hälbig, T. D.; Hesekamp, H.; Navarro, S. M.; Meier, Niklaus; Falk, D.; Mehdorn, M.; Paschen, S.; Maarouf, M.; Barbe, M. T.; Fink, G. R.; Kupsch, A.; Gruber, D.; Schneider, G.-H.; Seigneuret, E.; ... (2013). Neurostimulation for Parkinson's disease with early motor complications. New England journal of medicine NEJM, 368(7), pp. 610-622. Massachusetts Medical Society MMS 10.1056/NEJMoa1205158
The New England Journal of Medicine, 368, 610-22
New England Journal of Medicine, Vol. 368, No 7 (2013) pp. 610-622
The New England Journal of Medicine, 368, 7, pp. 610-22
Item does not contain fulltext BACKGROUND: Subthalamic stimulation reduces motor disability and improves quality of life in patients with advanced Parkinson's disease who have severe levodopa-induced motor complications. We hypothesized that neurosti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::111d2d21833897d075dd241498e679f2
https://doi.org/10.1056/nejmoa1205158
https://doi.org/10.1056/nejmoa1205158
Publikováno v:
Behavioural Brain Research. 170:337-341
Chronic daily administration of 6.25mg/kg of levodopa in unilaterally 6-OHDA lesioned rats did not induce any observable behavioral effects for the first 12.5+/-2.5 days. Thereafter, levodopa administration induced abnormal involuntary movements (AIM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b1fb35743219019127cff839e866846
https://doi.org/10.1016/j.bbr.2006.02.030
https://doi.org/10.1016/j.bbr.2006.02.030
Publikováno v:
Movement Disorders, Vol. 17 Suppl 3 (2002) pp. S188-97
The postoperative neurologic management of patients with deep brain stimulation (DBS) of the subthalamic nucleus (STN) for Parkinson' s disease is a complex dynamic process that involves a progressive increase in stimulation intensity and a parallel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b0a7a5579f60a931488ccecdfb81d7f
https://doi.org/10.1002/mds.10163
https://doi.org/10.1002/mds.10163
AIM: Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an established therapy for patients with Parkinson's disease (PD) associated with motor complications of long term L-dopa treatment. MATERIAL AND METHODS: Here we report two cases
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3566::61be4747b9a343c873338e4c94408cf6
Autor:
Valérie Fraix, Eugénie Lhommée, Bettina Debû, Pierre Pollak, Stephan Chabardes, Paul Krack, Alim-Louis Benabid, Claire Ardouin, Eric Seigneuret, Murielle Ursulla Ferraye
Publikováno v:
European Neurology, Vol. 69, No 5 (2013) pp. 281-288
We examined executive functioning in patients with Parkinson's disease exhibiting, or not, levodopa-resistant freezing of gait (L-FOG). 38 advanced-stage patients with L-FOG were identified in a consecutive series of 400 patients. They were matched w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4dfd90ba229fa480538ae167efe52561
https://pubmed.ncbi.nlm.nih.gov/23445615
https://pubmed.ncbi.nlm.nih.gov/23445615
Autor:
Magaly Aya Kombo, Valérie Fraix, Eugénie Lhommée, Eric Seigneuret, Stephan Chabardes, Sebastien Carnicella, Jean-Louis Quesada, Stéphane Thobois, Paul Krack, Jean-Luc Bosson, Patrick Mertens, Alim-Louis Benabid, Emmanuelle Schmitt, Hélène Klinger, Jing Xie, Andrea Kistner, Amélie Bichon, Claire Ardouin, Emmanuel Broussolle, Gustavo Polo, Pierre Pollak
Publikováno v:
Brain, Vol. 135, No Pt 5 (2012) pp. 1463-77
Addictions to dopaminergic drugs or to pleasant behaviours are frequent and potentially devastating neuropsychiatric disorders observed in Parkinson's disease. They encompass impulse control disorders, punding and dopamine dysregulation syndrome. A r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::213e54e2aa0aeb754c890e333fd7e708
https://archive-ouverte.unige.ch/unige:32810
https://archive-ouverte.unige.ch/unige:32810
Publikováno v:
Clinical Interventions In Aging, vol. 5, pp. 229-238
After more than 40 years of clinical use, levodopa (LD) remains the gold standard of symptomatic efficacy in the drug treatment of Parkinson's disease (PD). Compared with other available dopaminergic therapies, dopamine replacement with LD is associa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1900::62b45aa93c978945c7c32c37a0232e8f
https://serval.unil.ch/resource/serval:BIB_312BEA16C2AD.P001/REF.pdf
https://serval.unil.ch/resource/serval:BIB_312BEA16C2AD.P001/REF.pdf
Publikováno v:
Revue neurologique, Vol. 165, No 11 (2009) pp. 845-856
The common perception that Parkinson's disease patients tend to be depressed, anxious, apathetic and harm-avoiding has currently been challenged by the recognition that they can also exhibit a hedonistic, novelty-seeking personality. Thus, Parkinson'
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1400::824b40b546029be24653391dbf3a96ca
https://archive-ouverte.unige.ch/unige:19486
https://archive-ouverte.unige.ch/unige:19486
Autor:
Marie-Laure Welter, Valérie Fraix, Alexandra Durr, Pierre Pollak, Marie-Laure Tanguy, Paul Krack, Alexis Brice, Suzanne Lesage, Ebba Lohmann, Yves Agid, Valérie Mesnage, Jean-Luc Houeto, Sophie Laine
Publikováno v:
Movement Disorders
Movement Disorders, Wiley, 2008, 23 (5), pp.740-3. ⟨10.1002/mds.21903⟩
Movement Disorders, 2008, 23 (5), pp.740-3. ⟨10.1002/mds.21903⟩
Movement Disorders, Vol. 23, No 5 (2008) pp. 740-743
Movement Disorders, Wiley, 2008, 23 (5), pp.740-3. ⟨10.1002/mds.21903⟩
Movement Disorders, 2008, 23 (5), pp.740-3. ⟨10.1002/mds.21903⟩
Movement Disorders, Vol. 23, No 5 (2008) pp. 740-743
International audience; Patients with parkin mutations are known to have slower PD progression and a better response to levodopa at lower doses than patients with idiopathic Parkinson's disease. To determine the effects of deep brain stimulation (DBS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d56953b1dc9919e03457b4f3d2fecd23
https://www.hal.inserm.fr/inserm-00391529
https://www.hal.inserm.fr/inserm-00391529